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Depigmentation Therapies in 
Vitiligo
Sanjeev Mulekar, Madhulika Mhatre and Swapnil Mulekar
Abstract
Vitiligo is a chronic condition characterized by white patches on normal-
appearing skin. It runs an unpredictable course. Main reason of stress in vitiligo 
patients is the presence of two colors on the skin surface. The aim of the treatment 
is to achieve normal skin color. Depigmentation is considered when repigmentation 
is not possible or the patient is willing to accept that repigmentation is not possible 
and opt for irreversible depigmentation. The only agent approved for depigmenta-
tion is monobenzyl ether of hydroquinone or monobenzone for patients with more 
than 50% of body surface area affected with vitiligo. The scope of this chapter is to 
describe modality of depigmentation and its risks and benefits.
Keywords: extensive vitiligo, vitiligo, depigmentation, MBEH
1. Introduction
Vitiligo is a skin condition characterized by loss of pigments on normal skin 
with a worldwide prevalence of 0.1–2%. Due to its cosmetic impact, vitiligo can 
impact the quality of life in children and adults. There are multiple therapies used 
for repigmentation beginning from topical corticosteroids, calcineurin inhibitors, 
and narrowband ultraviolet B (NB-UVB) to oral systemic medications and surgery. 
Even though a good number of patients may achieve successful repigmentation, 
there may be a few in whom the progression of vitiligo may affect extensive body 
surface areas making repigmentation an uphill task. The aim in such patients with 
extensive vitiligo (more than 50% body surface area) would be to achieve a uniform 
skin tone by depigmenting the remaining pigmented sites [1].
Depigmentation therapy is an accomplishable alternative therapy in patients 
who are extensively affected by vitiligo. It can be used in all skin types. Most readily 
used and available depigmenting agents are monobenzyl ether of hydroquinone 
(MBEH), 4-methoxyphenol, and phenol. Other therapies such as lasers and cryo-
therapy have also been used. The depigmentation process is a gradual one and can 
take anywhere between 1 and 3 years. In the author’s experience, those who have 
undergone depigmentation are satisfied and happy with the therapeutic outcome if 
one achieves uniform color.
1.1 What the research says
The depigmentation approach is quite recent and is derived from the 
observations of unwanted depigmenting action of the phenol derivatives [2]. 
However, there are very few published studies on it. The aim of the researchers 
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was to explain the possible mechanism of action for this class of compounds. 
Tyrosinase was the first suggested target. Also the potential of different phenol 
derivatives to act as an alternative substrate of the enzyme or as a competitive 
inhibitor was evaluated. Thus, it was hypothesized that this class of substances, 
or some of them, may be used for the treatment of skin disorders caused due 
to hyperpigmentation or melanocyte hyperproliferation. Further structural 
studies have indicated that the role of the position and type of substitutes in the 
phenolic ring allow the compound to be hydroxylated or oxidated by tyrosinase 
[3]. Considering phenol derivatives have a role in this process, hydroquinone was 
evaluated. Hydroquinone (HQ ) belongs to the phenol/catechol class of chemical 
agents. Tyrosinase gets inhibited by HQ when interaction occurs with copper at 
the active site. This further decreases the amount of intracellular glutathione and 
induces the production of oxygen-reactive species. Thus, HQ acts as an alterna-
tive substrate, according to most part of phenol/catechol compounds, because it 
is similar to tyrosine. The enzyme can thus oxidize HQ without generating the 
pigment. The quinones produced are able to react with the sulfhydryl residues 
of the proteins, generating oxidative damage and affecting the cell growth. The 
depigmenting action is the result of the oxidative damage, involving both lipids 
and proteins of the cellular membranes. Functional studies have demonstrated 
that HQ and other phenolic compounds, such as tert-butylphenol, may even act 
through different mechanisms, including the oxidation of TRP1, and by interfer-
ing with RNA and DNA synthesis. HQ has been identified as the main depig-
menting agent, whereas among the various phenolic derivatives, the monobenzyl 
ether of hydroquinone (MBEH) appeared as the more handful one. In this 
chapter, we will review and compare various established and potential depig-
mentation agents as well as emerging therapies that can be used in extensive and 
universal vitiligo.
2. Selecting the right candidate
Selection of an appropriate patient is of utmost importance in depigmentation 
therapy. The option of depigmentation should be made available to only those 
patients having extensive vitiligo. Detailed and thorough consultation sessions 
should be conducted with the patient and their families (preferably 2–3 sessions), 
explaining to them in detail that this therapeutic modality utilizes a potent depig-
menting agent and should not be used for cosmetic purposes [2, 3]. They should be 
explained with all realistic expectations, treatment time frame, the cost involved, 
and side effects if any, and that once one particular type of treatment is done, they 
will not be a good candidate for any other type of treatment. Subjects with skin 
types (V and VI) with a disfiguring contrast between dark-pigmented skin and 
white vitiliginous areas, especially involving exposed areas (face or the hands), 
may be a candidate for depigmentation. Moreover, incomplete or trichrome repig-
mentation (e.g., when using UV light) may cause more disfigurement, thus making 
such individuals good candidates for depigmentation therapy. The patients should 
be informed that even after depigmentation, spontaneous repigmentation might 
occur in vitiligo lesions, warranting additional depigmenting cycles. Patients must 
be informed that these treatments lead to a definitive irreversible depigmentation. 
Younger patients with extensive involvement can be given an option of repigmenta-
tion instead of opting for depigmentation explaining that complete repigmentation 
may or may not be achieved. Depigmentation therapy should be avoided in children 
less than 12 years of age [4].
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3. Topical therapies for depigmentation
3.1 Monobenzyl ether of hydroquinone (MBEH)
MBEH (monobenzone, p-benzyloxy-phenol) is the most common topical 
depigmenting agent used mainly because it is the only product approved by the 
United States Food and Drug Administration (USFDA) for depigmentation in 
vitiligo, if the affected body surface area is more than 50% [1]. It is a hydroquinone 
(HQ ) derivative and was first introduced in 1930s. MBEH is the first-line agent for 
depigmentation therapy in vitiligo patients.
3.1.1 Mechanism of action
There are multiple pathways through which MBEH causes depigmentation [5]:
1. Reaction with tyrosinase enzyme during melanin synthesis leads to conver-
sion of MBEH to quinones. The reactive quinone products formed bind with 
cysteine found in tyrosinase proteins (sulfhydryl (-SH) group) to form hapten-
carrier compounds resulting in formation of neoantigens. These neoantigens 
stimulate a systemic, melanocyte destruction and an inflammatory reaction.
2. Another result of MBEH conversion by tyrosinase is production of reactive 
oxygen species (ROS). ROS leads to lysosomal degradation of melanosomes. 
Additionally, there is interference of the melanosome structure and mem-
branes, following which the major histocompatibility complex (MHC) class I 
and II routes and initiation of melanocyte Ag-specific T-cell responses cause an 
increase in surface expression of melanosomal antigens.
3. ROS also contributes to an innate immune response due to the release of 
exosomes.
4. MBEH-exposed skin presents with rapid and persistent innate immune activa-
tion. It is quoted by Gupta et al. “that MBEH is a contact-sensitizer, inducer 
of a type IV delayed type hypersensitivity response against the quinone 
hapten. However, this only occurs if there is production of pro-inflammatory 
cytokines such as interleukin (IL)-1b and IL-18 by the Langerhans cells or 
keratinocytes” [6]. 
There have been reports that when MBEH therapy was combined with all-trans 
retinoic acid (ATRA), it enhanced depigmentation process and the melanocytotoxic 
effects via inhibition of the enzyme glutathione S-transferase in melanocytes. This 
could be a possible way to avoid contact dermatitis when using high concentrations 
of 40% MBEH. However, combination of ATRA-MBEH did not affect hair pigmen-
tation in animal studies [7].
3.1.2 Administration of treatment
After the patient has been duly consulted and informed about all the possible 
outcomes and consequences of the treatment, the depigmentation therapy is 
initiated. Application of MBEH can be done by the patient at home. Initially, the 
exposed areas are treated. A test spot is advised over a normal pigmented skin 
(usually forearm) to assess the development of contact dermatitis. If there is no 
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adverse reaction, the patient can continue with the application of the cream on the 
areas of top priority and then move in stages for low priority areas. To avoid contact 
dermatitis, different concentrations of MBEH can be used. MBEH can be diluted to 
5% for use on the neck, 10% on the face, and 20% on the arms and legs. In patients 
who fail to respond to 20% MBEH over a course of 3 to 4 months, the concentration 
of MBEH can be increased to 30% and then further to 40%. Concentrations of 30 
and 40% MBEH have been used primarily on the extremities, especially the elbows 
and knees. Concentrations greater than this are not recommended [8].
It takes anywhere between 4 and 12 months for gradual depigmentation [8]. It is 
to be noted that depigmentation is mostly irreversible and histologically associated 
with loss of melanosomes and melanocytes [1].
3.1.3 Precautions
Patients should always be informed and well instructed about certain precau-
tions while using MBEH.
1. Application of MBEH at one site can lead to loss of pigment at distant body 
sites, i.e., application of MBEH to the arm may result in loss of pigment on the 
face [4]. Moreover, it can also reactivate a stable disease.
2. Application of MBEH to the eyelids is not advised [8] because of risk of 
ochronosis. It may lead to pigmentation of the conjunctiva if MBEH is applied 
on the eyelids.
3. Avoid skin-to-skin contact on a continuous basis with another person as it can 
cause a decrease in pigmentation at the site of contact in the other person.
4. The use of sunscreens with a high-sun protection factor (SPF) is essential. This 
also helps to prevent repigmentation as well as sunburn reactions [4].
5. Follicular repigmentation may occur spontaneously upon sun exposure [8]. 
This happens mainly because MBEH only destroys epidermal melanocytes 
keeping follicular melanocytes intact.
3.1.4 Side effects
Irritant contact dermatitis and common allergic reactions can develop [9]. In 
which event, application of MBEH is stopped, and open wet dressings are applied 
to the affected area along with topical steroids. Once the dermatitis has subsided, 
MBEH can be restarted at a lower concentration of 5% [8]. Other side effects 
include exogenous ochronosis [10], unmasking of telangiectasias and phlebectasias 
on the lower extremities [8], pruritus, xerosis, erythema, rash, edema, conjunctival 
melanosis, and distant depigmentation [4].
Risk of carcinogenesis with MBEH has not been reported but cannot be ruled 
out, and hence it is banned from the European Union since 2001 in cosmetics [11].
3.1.5 Combination therapy
All-trans retinoic acid (RA), which is a vitamin A derivative primarily employed 
in the treatment of acne, is shown to serve as a weak depigmenting agent when used 
for several weeks.
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A combination or RA and MBEH induced significant depigmentation within 
4–8 weeks. Nair et al. proposed that RA might enhance the skin penetration of 
depigmenting agents. Thus, RA increases the susceptibility of melanocytes to 
hydroquinone and 4-hydroxyanisole via the impairment of glutathione-dependent 
defense mechanisms of melanocytes and reducing melanogenesis activity in viable 
melanocytes [12–15].
3.2 Monomethyl ether of hydroquinone/4–0 methoxyphenol
This compound is a phenol derivative and is also known as p-hydroxyanisole 
(HA) or mequinol [1].
3.2.1 Mechanism of action
Mequinol acts in the similar way as MBEH acts. This compound usually acts via a 
dose-dependent response manner. It can be used as monotherapy or in conjunction 
with a Q-switched ruby laser.
3.2.2 Administration of treatment
The compound is used in a 20% concentration in an oil/water cream base. As 
with MBEH, cream is applied on an initial test patch to observe for any allergic 
reactions. If there are no reactions, the patient is advised to apply cream twice daily 
until complete depigmentation is observed [16]. The effectiveness of 4-MP has been 
correlated with the duration of the use of the cream; the longer the cream was used, 
better the results that were obtained [1].
A combination product of 2% 4-hydroxyanisole (mequinol) and 0.01% treti-
noin was tested in a double-blind multicentric study and was found to significantly 
improve solar lentigines and related hyperpigmented lesions of the face and hands 
after a twice-daily application of up to 24 weeks [1].
3.2.3 Side effects
Side effects include mild burning or itching, irregular leukoderma, contact der-
matitis, ochronosis, and risk of carcinogenesis cannot be ruled out [11]. Protection 
from sunlight is necessary or repigmentation risk is high [1, 11].
3.3 Phenol solution (88%)
Phenol is an inexpensive peeling agent having medium-depth capability and 
used for treatment of photodamage or rhytids. The toxicity of phenol toward 
melanocytes is well documented. Phenol has the ability to penetrate deeper into the 
tissue up to the upper reticular dermis.
3.3.1 Mechanism of action
Phenol is involved in melanogenesis, inducing coagulation of protein in 
the epidermis. The melanocytes lose their capacity to synthesize melanocytes 
normally. This property of phenol is different than that of MBEH and hydro-
quinone wherein they destroy the melanocytes [17]. Hence, 88% phenol can be 
used as therapeutic option to eliminate residual normally pigmented lesions in 
patients.
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3.3.2 Administration of treatment
The area to be treated is cleaned with spirit/alcohol. Application of phenol 
is done with the help of a swab soaked with phenol until cutaneous frosting 
occurs. There might be a burning sensation experienced by the patient for 
approximately 60 seconds, which gradually decreases in intensity but can last 
from minutes to hours. In a case study reported by Zanini and Machado Filho, 
they reported the use of 88% phenol on a 62-year-old female patient. Post 2 
sessions, with a gap of 45 days, total elimination of residual pigmentation was 
achieved [17].
3.3.3 Side effects
In general, 88% phenol does not produce any major complications when used 
in limited areas. However, some complications such as cardiotoxicity and other 
systemic toxicities have been reported in patients treated with medium and deep 
peeling over larger areas. Its cellular uptake is both rapid and passive because of 
its lipophilic character and signs of systemic toxicity develop soon after exposure. 
Cardiovascular shock, cardiac arrhythmias, and bradycardia, as well as metabolic 
acidosis, have been reported within 6 hours of skin-peeling procedures with phenol 
[17]. Other complications include non-esthetic scar formation, dyschromia, and 
development of herpetic eczema. However, the authors of this chapter have also 
noted a paradoxical response, wherein phenol application led to repigmentation of 
the skin!
4. Physical therapies for depigmentation
Depigmentation with topicals is effective; however, they come with their share 
of side effects and can take up to 10 months or more for completion of the process 
and rarely complete depigmentation may not be achieved. Depigmentation by 
physical means, i.e., by cryotherapy and lasers, can be done when rapid depigmen-
tation is desired or when patients have not responded well to topicals or have had 
contact dermatitis or any side effects due to the same.
4.1 Cryotherapy
Cryotherapy is nothing but cold therapy or the use of low temperatures to treat 
a variety of tissue lesions. With cryotherapy, it is possible to achieve rapid and 
permanent depigmentation via irreversible tissue damage resulting from intracel-
lular ice formation. Liquid nitrogen is used as a cryogen for clinical use. The degree 
of damage depends on the rate of cooling and minimum temperature achieved. 
Further, inflammation develops within 24 hours of the treatment, which contrib-
utes to destruction of lesions via immunologically mediated mechanisms. In areas 
of koebnerization, cryotherapy is more effective.
4.1.1 Procedure
Initially, spot testing by a single freeze-thaw cycle is done. Once the edema and 
erythema subside, patches are treated with cryotherapy 3–6 weeks later. Either 
CO2 or liquid N2 can be used. A 2-cm flat-topped and round cryoprobe is used at 
approximately 40 mm from the skin surface. The whole patch is frozen with a single 
freeze-thaw cycle from the periphery followed by forming successive rows inward. 
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Procedure should be terminated when a narrow (<1 mm) frost rim forms around 
the periphery of the cryoprobe. The rim can develop within 10–20 s by a cryogun 
connected to a container with barometric pressure above 80 kg/cm2. For lesions 
around the orbits or uneven areas of the nose, cryoprobes having smaller diameters 
may be required. No more than one freeze-thaw cycle is advised per session. There 
have been cases reported which have used two freeze-thaw cycles [18]. Results are 
visible by the end of 4 weeks after the procedure.
Alternatively, a cryospray/cryopen or the traditional dip-stick method of appli-
cation can be used following the same freeze-thaw cycle protocol.
4.1.2 Pros and cons
• Low cost and simple to perform.
• Does not require anesthesia.
• Minimal wound care with no dressing or antibiotics.
• Safe and efficacious.
• No scar formation if performed by an experienced dermatologist.
• It can be performed only on smaller areas.
• Multiple sittings may be required.
• If performed aggressively, it can lead to permanent scarring.
4.2 Laser therapy
Another faster method of depigmentation is the use of laser therapy. Lasers 
have been advocated more than MBEH and other bleaching agents due to their 
failure rate, as they have been proven to selectively destruct the melanocytes 
causing depigmentation. Further the risk of scar formation is minimized with laser 
therapies [16].
Mainly, the Q-switched ruby (QSR, 694 nm) and alexandrite (755 nm) lasers 
have been used in depigmentation. Both of these lasers operate in a similar manner 
in terms of mechanism of action. They induce photothermolysis of the pigmented 
lesions as they have wavelengths between 600 and 800 nm. These wavelengths 
are more readily and well absorbed by melanin. The frequency and pulse width 
is adjusted according to the skin type of the patient by a trained and experienced 
dermatologist. A maximum of 80 cm2 area is treated per session.
Q-switched ruby Q-switched alexandrite
• Selectively targets melanosomes and destroys 
melanocytes and keratinocytes
• Works better on tanned skin
• Fast and safe
• Duration of treatment is short
• Larger areas can be treated effectively
• Reduced risk of scar formation
• Is efficacious in treating naturally occurring 
pigmented lesions as well as exogenous pigments
• Safe, simple, and effective in treating recalcitrant 
pigmentation
• Faster pulse frequency, hence rapid therapy
• Higher wavelength so greater tissue penetration 
with improved results
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Some other potential Q-switched lasers that can selectively destruct melanocytes 
include neodymium:yttrium aluminum garnet (Nd:YAG) laser (1064 nm) and the 
frequency-doubled Q-switched Nd:YAG laser (532 nm) [1]. In a study by Boen et al., 
Q-switched ruby laser (QSRL) 694 nm, Q-switched alexandrite laser (QSAL) 755 nm, 
and picosecond 755-nm alexandrite lasers provided the most significant pigment 
reduction when different recalcitrant pigmented areas of the body were treated by 
the abovementioned lasers over different areas in the same patient. In all the patients 
treated with this laser therapy, no adverse reactions apart from mild postprocedure 
erythema and crusting were noticed. The picosecond laser poses more advantages 
over the traditional Q-switch laser as it has increased photochemical action due to 
shorter pulse duration, requires lesser treatment sessions, and has reduced specific 
photothermal damage. This results in an increase in the safety profile of the laser and 
improves the effectiveness of this therapeutic modality [19, 24–26].
4.2.1 Points to ponder
• Procedure is slightly painful and may require local anesthesia.
• Treatment is expensive.
• Possibility of failure in removing pigmented patches even after several treat-
ments because of Koebner’s phenomenon.
• Patients with active vitiligo respond better to laser treatments compared to 
those with stable vitiligo. Hence, patients who are Koebner negative may often 
relapse [16].
5. Emerging therapies for depigmentation
5.1 Imatinib
Also known as imatinib mesylate, it is used to treat conditions like leukemia and 
gastrointestinal stromal tumors. It was observed that patients treated with imatinib 
were reported to develop generalized depigmentation as a side effect. Imatinib is a 
tyrosinase kinase inhibitor, thus inhibiting the activity of the enzyme, resulting in 
decreased pigmentation of the skin. The side effects of imatinib include fluid reten-
tion, periorbital edema, diarrhea, and myelosuppression. Some of the dermatological 
side effects include erythroderma, follicular mucinosis, and lichenoid eruption [27].
5.2 Imiquimod
Imiquimod is usually used for topical treatment of anogenital warts and basal cell 
carcinomas [20]. It is an imidazoquinoline and is an immune response modifier. It 
acts by stimulating the monocytes/macrophages and plasmacytoid dendritic cells in 
dermis and epidermis of the immune system to produce pro-inflammatory cytokines, 
mainly interferon α and other signals that activate T-cell-mediated response leading to 
apoptosis of tumor cells. Prolonged use of imiquimod has shown to result in depig-
mentation [1]. Imiquimod also stimulates CD8 cells to become cytotoxic and enhances 
antigen presentation [21]. Recently, it was reported that human melanocytes express 
toll-like receptor 7 (TLR7). When applied topically, imiquimod binds to TLR7 
followed by stimulation of various cytokines, which induce the abovementioned 
T-lymphocytic response [22]. Imiquimod also has a direct action on melanocytes via 
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apoptosis of melanocytes. This action is related to reduction of expression of Bcl-2 
and/or an increase in the proapoptotic stimulus (cytotoxic T lymphocytes, natural 
cytotoxic T cells/killer cells, granzymes B, Fas, TNF, Bax, etc.) [23].
Thus, there is a strong possibility that imiquimod may cause elimination of 
melanocytes by direct influence on cells as well as inducing acquired immunity 
indirectly, which eventually induces vitiligo-like hypopigmented lesions [28]. 
Some common side effects include itching, pain, burning, erosions, erythema, and 
crusting.
5.3 Diphencyprone (DPCP)
DPCP is used traditionally as a treatment modality for alopecia areata. 
Depigmentation was found to be one of the side effects due to the use of DPCP. It 
has an immunomodulatory mechanism of action. As reported by Duhra and Foulds 
[12], in a case of alopecia totalis where topical DPCP was used, there a was marked 
reaction with erythema and edema on the forearm after 3 days, but the scalp mani-
fested only slight macular erythema. The reaction on the forearm subsided after 
2 weeks and was replaced by a depigmented patch over a period of 6 weeks. Upon 
incubating the affected skin with dopa followed by electron microscopy, an absence 
of melanosomes and melanocytes was revealed. It has been observed that vitiligo 
can develop even with DPCP concentrations as low as 0.0001% [12].
Some of the adverse effects include hyperpigmentation, regional lymphade-
nopathy, blistering, and eczematous reactions [20].
6. Limitations
The science of depigmentation is still not a perfected one and that does leave 
many questions unanswered. Further research in this arena can help shed light on 
these doubts:
1. Aspects that cannot be controlled
a. Remote depigmentation.
b. End result (color matching or same color).
c. Hairs do not lose pigment (can give repigmentation especially follicular).
d. Repigmentation during pregnancy (at times extensive).
e. Resistance to MBEH.
2. Can patients with less than 50% involvement, willing to accept that no more 
repigmentation is possible, are candidates for depigmentation?
3. Whether depigmentation in children is a safe and viable alternative?
7. Conclusion
Vitiligo has a huge psychological impact and is also socially stigmatizing, 
particularly for patients with darker skin types in whom the contrast between the 
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vitiliginous lesions and uninvolved skin can be especially apparent and disfiguring. 
In patients with widespread involvement covering more than 50% of their body 
and in cases where medical modalities including phototherapy have proved inef-
fective, depigmentation therapy should be considered. Patient selection, adequate 
counseling, and patient education are extremely important for a positive long-term 
outcome.
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